Search
Precision BioSciences Inc
DTILAdd to Watchlist
6.330USD
-0.030-0.47%
Close 09-23 16:00（ET）
163.31MMarket Cap
LossP/E TTM
About Precision BioSciences Inc Company
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Precision BioSciences Inc Profile
Ticker SymbolDTIL
Company namePrecision BioSciences Inc
IPO dateMar 28, 2019
CEOAmoroso (Michael)
Number of employees108
Security typeOrdinary Share
Fiscal year-endMar 28
Address302 E Pettigrew St Ste A100
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27701-2393
Phone19193145512
Websitehttps://precisionbiosciences.com/
Ticker SymbolDTIL
IPO dateMar 28, 2019
CEOAmoroso (Michael)
Company Executives of Precision BioSciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
Ms. Melinda Brown
Ms. Melinda Brown
Independent Director
Independent Director
44.35K
+47.35%
Ms. Melinda Brown
Ms. Melinda Brown
Independent Director
Independent Director
44.35K
+47.35%
Ms. Melinda Brown
Ms. Melinda Brown
Independent Director
Independent Director
44.35K
+47.35%
Mr. Naresh Tanna
Mr. Naresh Tanna
Chief Financial Officer
Chief Financial Officer
25.57K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.39K
--
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
44.88K
+46.79%
FAQs
Who are the top five shareholders of Precision BioSciences Inc?
The top five shareholders of Precision BioSciences Inc are: Mr. Michael Amoroso
How many institutions hold shares of Precision BioSciences Inc (DTIL)?
As of 2026Q1, 129 institutions hold shares of Precision BioSciences Inc, with a combined market value of approximately 15.71M, accounting for 60.88% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3015080.00.